Kimelman & Baird LLC Lowers Stake in STERIS plc (NYSE:STE)

Kimelman & Baird LLC reduced its stake in shares of STERIS plc (NYSE:STE) by 10.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,673 shares of the medical equipment provider’s stock after selling 3,026 shares during the quarter. Kimelman & Baird LLC’s holdings in STERIS were worth $5,277,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in STE. Avalon Trust Co purchased a new stake in shares of STERIS during the fourth quarter valued at $30,000. Human Investing LLC purchased a new stake in shares of STERIS during the fourth quarter valued at $31,000. Anfield Capital Management LLC boosted its stake in shares of STERIS by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 91 shares during the period. Central Pacific Bank Trust Division boosted its stake in shares of STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 76 shares during the period. Finally, Manchester Capital Management LLC boosted its stake in shares of STERIS by 182.7% during the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 137 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

STE has been the subject of several recent research reports. JMP Securities restated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a report on Thursday, February 6th. Stephens restated an “overweight” rating and issued a $240.00 price objective on shares of STERIS in a report on Thursday, February 6th. Finally, Piper Sandler lifted their price objective on STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $258.75.

STERIS Stock Performance

Shares of STERIS stock opened at $227.04 on Monday. The company has a market capitalization of $22.31 billion, a PE ratio of 48.20 and a beta of 0.92. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13. The company has a 50-day simple moving average of $219.17 and a two-hundred day simple moving average of $222.38. STERIS plc has a one year low of $197.82 and a one year high of $248.24.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Research analysts expect that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Shareholders of record on Thursday, February 20th will be issued a $0.57 dividend. The ex-dividend date is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a yield of 1.00%. STERIS’s dividend payout ratio is presently 48.41%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.